Improving smoking cessation approaches at the individual level

Tobacco Control

Volumn 21, Issue 2, 2012, Pages 252-257

  Aveyard, Paul ^a   Raw, Martin ^b,c  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE GUM;

ARTICLE; BEHAVIOR THERAPY; HUMAN; METHODOLOGY; PUBLIC HEALTH; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE;

BEHAVIOR THERAPY; HUMANS; PUBLIC HEALTH; SMOKING; SMOKING CESSATION; TOBACCO USE CESSATION PRODUCTS; TOBACCO USE DISORDER;

EID: 84857326094     PISSN: 09644563     EISSN: 14683318     Source Type: Journal    
DOI: 10.1136/tobaccocontrol-2011-050348     Document Type: Article

References (73)

1. Breslau N, Kilbey M, Andreski P. DSM-III-R nicotine dependence in young adults: prevalence, correlates and associated psychiatric disorders. Addiction 1994;89:743-54.
2. Benowitz NL. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther 2008;83:531-41
3. Hughes JR. Effects of abstinence from tobacco: etiology, animal models, epidemiology, and significance: a subjective review. Nicotine Tob Res 2007;9:329-39.
4. Hughes JR. Effects of abstinence from tobacco: valid symptoms and time course. Nicotine Tob Res 2007;9:315-27.
5. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 2004;99:29-38.
6. Aveyard P, Brown K, Saunders C, et al. A randomised controlled trial of weekly versus basic smoking cessation support in primary care. Thorax 2007;62:898-903
7. Balfour DJ. The neurobiology of tobacco dependence: a preclinical perspective on the role of the dopamine projections to the nucleus. Nicotine Tob Res 2004;6:899-912.
8. Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 2004;328:1519.
9. Critchley J, Capewell S. Smoking cessation for the secon dary prevention of coronary heart disease. Cochrane Database Syst Rev 2003;(4):CD003041.
10. Parsons A, Daley A, Begh R, et al. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 2010;340:b5569.
11. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977;1:1645-8.
12. Soriano JB, Sin DD, Zhang X, et al. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest 2007;131:682-9.
13. Gritz ER, Nisenbaum R, Elashoff RE, et al. Smoking behavior following diagnosis in patients with stage I non-small cell lung cancer. Cancer Causes Control 1991;2:105-12.
14. Franco OH, Peeters A, Bonneux L, et al. Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women: life course analysis. Hypertension 2005;46:280-6.
15. Prospective Studies Collaboration, Whitlock G, Lewington S, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009;373:1083-96.
16. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) Diet. N Engl J Med 2001;344:3-10.
17. National Institute for Health and Clinical Excellence. Guidance on the Use of Nicotine Replacement Therapy (NRT) and Bupropion for Smoking Cessation. 2002:1-27. http://www.nice.org.uk/nicemedia/pdf/NiceNRT39GUIDANCE.pdf (accessed 16 Feb 2008).
18. Zhu SH, Lee M, Zhuang YL, et al. Interventions to increase smoking cessation at the population level: How much progress has been made in the last two decades? Tob Control 2012;21:110-18.
19. Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation. Cochrane Database. Syst Rev 2008;(2):CD000165.
20. Aveyard P, Parsons A, Begh R, et al. Brief opportunistic smoking cessation interventions: a systematic review and meta-analysis to compare advice to quit and offer of assistance. Addiction Published online first 16 Dec 2011. doi:10.1111/j.1360- 0443.2011.03770.x
21. West R, Shiffman S. Effect of oral nicotine dosing forms on cigarette withdrawal symptoms and craving: a systematic review. Psychopharmacology (Berl) 2001;155:115-22.
22. West R, Baker C, Cappelleri J, et al. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology (Berl) 2008;197:371-7.
23. Medicines and Healthcare Regulatory Authority. Report of the Committee on Safety of Medicines Working Group on Nicotine Replacement Therapy. 2005. http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON2022933 (accessed 13 Nov 2011).
24. Rose JE. Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology (Berl) 2006;184:274-85.
25. Royal College of Physicians. Nicotine Addiction in Britain. A report of the Tobacco Advisory Group of the Royal College of Physicians. London: Royal College of Physicians of London, 2000.
26. Shiffman S, Shadel WG, Niaura R, et al. Efficacy of acute administration of icotinegum in relief of cue-provoked cigarette craving. Psychopharmacology (Berl) 2003;166:343-50.
27. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008;(1):CD000146.
28. Sutherland G, Stapleton JA, Russell MA, et al. Randomised controlled trial of nasal nicotine spray in smoking cessation. Lancet 1992;340:324-9.
29. Stapleton JA, Sutherland G. Treating heavy smokers in primary care with the nicotine nasal spray: randomized placebo-controlled trial. Addiction 2011;106:824-32.
30. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007;(1):CD006103
31. Hajek P, McRobbie HJ, Myers KE, et al. Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates. Arch Intern Med 2011;171:770-7.
32. Lindson N, Aveyard P. An updated meta-analysis of nicotine preloading for smoking cessation: investigating mediators of the effect. Psychopharmacology (Berl) 2011;214:579-92.
33. Etter JF. Cytisine for smoking cessation: a literature review and a meta-analysis. Arch Intern Med 2006;166:1553-9.
34. West R, Zatonski W, Cedzynska M, et al. Randomized placebo-controlled trial of cytisine for smoking cessation. N Engl J Med 2011;365:1193-200.
35. Gierisch JM, Bastian LA, Calhoun PS, et al. Comparative effectiveness of smoking cessation treatments for patients with depression: a systematic review and meta- analysis of the evidence. 2010. http://www.hsrd.research.va.gov/publications/esp/smoking-cessation-2010.pdf VA-ESP Project #09-010. (accessed 13 Jun 2011).
36. Lerman C, Niaura R, Collins BN, et al. Effect of bupropion on depression symptoms in a smoking cessation clinical trial. Psychol of Addict Behav 2004;18:362-6.
37. Covey LS, Glassman AH, Stetner F, et al. A randomized trial of sertraline as a cessation aid for smokers with a history of major depression. Am J Psychiatry 2002;159:1731-7.
38. Cipriani A, La FT, Furukawa TA, et al. Sertraline versus other antidepressive agents for depression. [Review] [140 refs] Update in Cochrane Database Syst Rev 2010;(4):CD006117. PMID: 20393946].[Update of Cochrane Database Syst Rev. 2009;(2):CD006117; PMID: 19370626]. Cochrane Database of Systematic Reviews. 2010;CD006117.
39. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2004;(4):CD000031.
40. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2005;(2):CD001292.
41. Abraham C, Michie S. A taxonomy of behavior change techniques used in interventions. Health Psychol 2008;27:379-87.
42. Michie S, Churchill S, West R. Identifying evidence-based competences required to deliver behavioural support for smoking cessation. Ann Behav Med 2011;41:59-70.
43. Michie S, Hyder N, Walia A, et al. Development of a taxonomy of behaviour change techniques used in individual behavioural support for smoking cessation. Addict Behav 2011;36:315-19.
44. West R, Walia A, Hyder N, et al. Behavior change techniques used by the English Stop Smoking Services and their associations with short-term quit outcomes. Nicotine Tob Res 2010;12:742-7.
45. Stead LF, Perera R, Lancaster T. Telephone counselling for smoking cessation. Cochrane Database Syst Rev 2006;(3):CD002850.
46. Shahab L, McEwen A. Online support for smoking cessation: a systematic review of the literature. Addiction 2009;104:1792-804.
47. Whittaker R, Borland R, Bullen C, et al. Mobile phone-based interventions for smoking cessation. Cochrane Database Syst Rev 2009;(4):CD006611.
48. Free C, Knight R, Robertson S, et al. Smoking cessation support delivered via mobile phone text messaging (txt2stop): a single-blind, randomised trial. Lancet 2011;378:49-55.
49. Piasecki TM, Jorenby DE, Smith SS, et al. Smoking withdrawal dynamics: I. Abstinence distress in lapsers and abstainers. J Abnorm Psychol 2003;112:3-13.
50. Hajek P, Stead LF, West R, et al. Relapse prevention interventions for smoking cessation. Cochrane Database Syst Rev 2009;(1):CD003999.
51. Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006;296:64-71.
52. Hajek P, Tonnesen P, Arteaga C, et al. Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatment. Addiction 2009;104:1597-602.
53. Nabi Biopharmaceuticals Announces Results of First NicVAX(R) Phase III ClinicaldConference Call. 2011. http://phx.corporate-ir.net/phoenix.zhtml?p1/4irol-eventDetails&c1/4100445&eventID1/44158429 (accessed 13 Oct 2011).
54. West R, Fidler JA. Key findings from the Smoking Toolkit Study. STS 014. London: UCL, 2011. http://www.smokinginengland.info/ (accessed 29 Mar 2011).
55. Taylor T, Lader D, Bryant A, et al. Smoking-Related Behaviour and Attitudes, 2005. London: Office for National Statistics, 2006.
56. Hammond D, Reid JL, Driezen P, et al. Smokers' use of nicotine replacement therapy for reasons other than stopping smoking: findings from the ITC Four Country Survey. Addiction 2008;103:1696-703.
57. Shiffman S, Hughes JR, Ferguson SG, et al. Smokers' interest in using nicotine replacement to aid smoking reduction. Nicotine Tob Res 2007;9:1177-82.
58. Cheong Y, Yong HH, Borland R. Does how you quit affect success? A comparison between abrupt and gradual methods using data from the International Tobacco Control Policy Evaluation Study. Nicotine Tob Res 2007;9:801-10.
59. West R, McEwen A, Bolling K, et al. Smoking cessation and smoking patterns in the general population: a 1-year follow-up. Addiction 2001;96:891-902.
60. Lindson N, Aveyard P, Hughes JR. Reduction versus abrupt cessation in smokers who want to quit. Cochrane Database Syst Rev 2010;(3):CD008033
61. Moore D, Aveyard P, Connock M, et al. Nicotine replacement therapy assisted reduction to stop smoking: a systematic review and meta-analysis of effectiveness and safety. BMJ 2009;338:b1024.
62. Aveyard P, Lindson N. Commentary on Chan et al. (2011): smoking reductiondwhere are we now? Addiction 2011;106:1164-5.
63. Cinciripini PM, Lapitsky L, Seay S, et al. The effects of smoking schedules on cessation outcome: can we improve on common methods of gradual and abrupt nicotine withdrawal? J Consult Clin Psychol 1995;63:388-99.
64. National Institute for Health and Clinical Excellence. Guidance on Smoking Cessation. 2008.
65. Fiore MC, Jaen CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Washington DC: US Department of Health and Human Services, 2008:1-256.
66. Steinberg MB, Schmelzer AC, Richardson DL, et al. The case for treating tobacco dependence as a chronic disease. Ann Intern Med 2008;148:554-6.
67. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419.
68. Davey Smith G, Bracha Y, Svendsen KH, et al. Incidence of type 2 diabetes in the randomized multiple risk factor intervention trial. Ann Intern Med 2005;142:313-22.
69. Wannamethee SG, Shaper AG, Perry IJ, et al. Smoking as a modifiable risk factor for type 2 diabetes in middle-aged men. Diabetes Care 2001;24:1590-5.
70. Willi C, Bodenmann P, Ghali WA, et al. Active smoking and the risk of type 2 diabetes. JAMA 2007;298:2654-64.
71. Lycett D, Munafo M, Johnstone E, et al. Associations between weight change over 8 years and baseline body mass index in a cohort of continuing and quitting smokers. Addiction 2011;106:188-96.
72. Parsons AC, Shraim I, Inglis J, et al. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev 2009;(1):CD006219.
73. Raw M. The psychological treatment of smoking and current work at the Maudsley Smokers' Clinic. Health Magazine 1975;12:22-6.